BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Clinical Development Milestones Achieved for Avineuro CNS Collaboration with ChemDiv, Inc.


9/16/2009 11:02:16 AM

SAN DIEGO, CA--(Marketwire - September 16, 2009) - ChemDiv Inc. of San Diego, CA, and Avineuro Pharmaceuticals Inc. of San Diego, CA, announced successful milestones reached under ongoing research and development collaboration in area of neurodegenerative and psychiatric disorders. R&D services were provided by ChemDiv's subsidiary Chemical Diversity Research Institute, based in Moscow, Russia. The existing agreement provides for research funding for developing clinical candidate compounds to obtain Proof of Concept in man. Avineuro is responsible for further clinical development and commercialization of drug candidates, and additional compounds that may be nominated for development from the ongoing research and discovery under the agreement. In September 2008, ChemDiv entered into a collaboration agreement with Avineuro to develop multiple pre-clinical compounds for Alzheimer Disease and schizophrenia. Under the agreement ChemDiv provided pre-clinical development services to nominate additional backup leads and candidates for Avineuro. This collaboration led to the initiation of Phase I studies for two of the molecules in Avineuro's pipeline, as well as successful completion of Phase I studies and initiation of Phase II studies for the third molecule in Avineuro's pipeline.

About ChemDiv

ChemDiv Inc. (Chemical Diversity) is a global contract research organization accelerating external discovery and development of novel therapies through comprehensive Discovery outsource™ services, including discovery biology, medicinal and synthetic chemistry, and pre-clinical and clinical development.

About Avineuro Pharmaceuticals

Avineuro Pharmaceuticals, Inc. discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry.


Contacts:

Ronald Demuth
SVP & General Manager
ChemDiv, Inc.
6605 Nancy Ridge Drive
San Diego, CA 92121
Phone: (858) 794-4860
Fax: (858) 794-4931
Email Contact

Yan Lavrovsky
CEO Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES